Related Experiment Video
Updated: Jun 8, 2025
Measuring Local Anaphylaxis in Mice
Published on: October 14, 2014
A case with recurrent idiopathic anaphylaxis episodes starting soon after COVID-19 mRNA vaccination
Pelin Korkmaz1, Semra Demir2, Deniz Eyice Karabacak2
1Department of Internal Medicine, Division of Allergy and Clinical Immunology, Faculty of Medicine, Istanbul University, Istanbul, Turkey; dr.korkmazpelin@gmail.com.
Introduction:
A patient was presented with a history of idiopathic recurrent anaphylaxis after administration of Pfizer BioNTech mRNA vaccine, and the attacks were controlled with omalizumab. To our knowledge, this is the first reported case of recurrent idiopathic anaphylaxis (IA) after administration of Pfizer BioNTech mRNA vaccine.
Case Presentation:
A 52-year-old man with recurrent episodes of IA after COVID-19 vaccination presented to our adult Allergy and Immunology Clinic. In the patient, urticaria and anaphylaxis episodes could not be controlled with high-dose antihistamine and systemic steroid treatment, and complete control was achieved with omalizumab treatment and anaphylaxis attacks completely regressed.
Conclusion:
In cases of unexplained or recurrent anaphylaxis in adult patients, COVID-19 vaccination and timing should be questioned, and its association with anaphylaxis might be considered.
Related Concept Videos
02:06Allergic Reactions
00:42Cross-reactivity
01:30Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
01:51Vaccinations
01:23Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
01:27Allergic Drug Reactions